Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

L.A. McKeown

February 18, 2021

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Daily News

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Caitlin E. Cox

September 05, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

January 2026 Dispatch for the CV Team

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

TCTMD’s Top 10 Most Popular Stories for December 2023

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content